Company Overview of Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG, a pharmaceutical company, focuses on developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases. The company’s products pipeline includes AFC-5128, an oral CNS-penetrant P2X7 antagonist for the treatment of neuropathic pain and multiple sclerosis; and AFC-08, a TMEFF2 monoclonal antibody for the treatment of depression. It was formerly known as Neuronova AG and changed its name to Affectis Pharmaceuticals AG in January 2005. The company was founded in 2004 and is based in Dortmund, Germany. As of January 7, 2014, Affectis Pharmaceuticals AG operates as a subsidiary of LDC Beteiligungen UG (haftungsbeschränkt).
Founded in 2004
49 231 9742 7000
49 231 9742 7039
Key Executives for Affectis Pharmaceuticals AG
Similar Private Companies By Industry
|3B Pharmaceuticals GmbH||Europe|
|Accelsiors Group International||Europe|
|Aenova Group GmbH||Europe|
|Aenova Holding GmbH||Europe|
|AiCuris GmbH & Co. KG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Affectis Pharmaceuticals AG, please visit www.affectis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.